Rheumatology

Back to articles

Tocilizumab may be good option as first-line therapy for polymyalgia rheumatica

KEY POINT

Tocilizumab (Actemra—Genentech) monotherapy in glucocorticoid-free patients with recent-onset polymyalgia rheumatica was found to be effective, according to the results of a small, open-label study published online in the Annals of the Rheumatic Diseases.

SOURCES

Devauchelle-Pensec V, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: A prospective longitudinal study. Ann Rheum Dis. 2016;[Epub ahead of print].